2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1302

Silent Progression in Patients with Rheumatoid Arthritis: Is DAS28 Remission an Insufficient Goal in RA? Results from the German Remission-PLUS Cohort
Abstract Number: 1303

Extended T2-Times in Cardiovascular Magnetic Resonance (CMR) in Patients with Systemic Lupus Erythematosus (SLE) and Persisted Dyspnoea: Is SLE-Associated Myocarditis an Underestimated Problem?
Abstract Number: 1304

2D and 3D Measurements of Osteoarthritis Joint Space Width Have Good Agreement in Radiographically Normal Knees but Poor Agreement with Advancing Kellgren-Lawrence Grade: Data from the Osteoarthritis Initiative
Abstract Number: 1305

Enriching Rheumatoid Arthritis Trial Cohorts with Erosion Progressors By Screening for Active Erosions (Erosions with Osteitis) with MRI
Abstract Number: 1306

Magnetic Resonance Imaging Measures of Disease Activity in Rheumatoid Arthritis Patients Treated with Multiple Regimens of DMARD Therapy
Abstract Number: 1307

Anatomical Patterns Suggest the Involvement of Biomechanical Stress in the Pathogenesis of Erosions in Rheumatoid Arthritis
Abstract Number: 1308

MRI of Bilateral Hands Prevents Clinicians from Failing to Detect Joint Damage of Patients with Rheumatoid Arthritis Compared to Scanning Unilateral Hand
Abstract Number: 1309

The Incidence of Sexually Acquired Reactive Arthritis: A Systematic Literature Review
Abstract Number: 1310

Management of Chronic Post-Chikungunya Rheumatic Disease: The Martinican Experience
Abstract Number: 1311

Causative Pathogens, Antibiotic Susceptibility, and Characteristics of Patients with Bacterial Septic Arthritis over Time
Abstract Number: 1312

Incidence of Reactive Arthritis, Uveitis and Conjunctivitis in Japanese Patients with Bladder Cancer Following Intravesical BCG Therapy: A 20 Years’ Two-Center Retrospective Study
Abstract Number: 1313

Rheumatologic Diseases in HIV-Infected Patients in the Post-Antiretroviral Therapy Era: The County Experience
Abstract Number: 1314

Characteristics of the Musculoskeletal Symptoms Observed Among Survivors of Ebola Virus Disease (EVD) in the Postebogui Cohort in Guinea
Abstract Number: 1315

Methotrexate and TNF-Blockers for Post Chikungunya Chronic Arthritis : The Martinican Experience
Abstract Number: 1316

Clinical Features and Outcomes of Prosthetic Joint Septic Arthritis: The Gender Effect

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].